Hemoglobin News and Research

RSS

Antiwasting supplements provide moderate improvements in child health

Study results show that ready-to-use supplementary food, provided to children at risk for malnutrition as part of a general food distribution program, does not significantly improve child weight.

20 Sep 2012

Researchers to probe causes, treatments of toxic reactions in blood plasma

In the largest undertaking of its kind, scientists at four leading U.S. research institutions are embarking upon a five-year National Institutes of Health (NIH)-funded study to make blood transfusions safer and more effective by uncovering the exact causes of hemoglobin toxicity.

18 Sep 2012

ASN's top five recommendations to avoid wasteful and harmful medical interventions

Earlier this year, the American Society of Nephrology (ASN), the world's leading kidney organization, joined other groups in a campaign to help health care professionals and patients avoid wasteful and sometimes harmful medical interventions. A new article in the Clinical Journal of the American Society of Nephrology (CJASN) outlines the ASN's top five recommendations for the campaign and the rationale behind them.

14 Sep 2012

Physician empathy has positive impact on patient outcomes

Patients of doctors who are more empathic have better outcomes and fewer complications, concludes a large, empirical study by a team of Thomas Jefferson University and Italian researchers who evaluated relationships between physician empathy and clinical outcomes among 20,961 diabetic patients and 242 physicians in Italy.

10 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

Herpes virus eventually impairs glucose regulation

The common herpes virus cytomegalovirus may be a risk factor for the development of Type 2 diabetes among elderly individuals, show study findings.

3 Sep 2012

Low blood pressure increases diabetes mortality risk

Tight blood pressure control fails to confer a survival benefit in patients newly diagnosed with Type 2 diabetes, and may even increase mortality risk when low blood pressure levels are achieved, UK investigators have discovered.

3 Sep 2012

Diabetes prevention: an interview with Julian Baines, CEO of EKF Diagnostics

NICE public health guideline 38 ‘Preventing type 2 diabetes: Risk identification and interventions for individuals at high risk’.

From EKF Diagnostics 3 Sep 2012

Targeted intervention improves safety of MRI scans for children with sickle cell disease

Jude Children's Research Hospital reports success using a targeted educational approach to teach young patients to remain motionless during MRI scans, making the process safer.

1 Sep 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Study investigates effects of passive smoking on the levels of three parameters

"It is well known that passive smoking is harmful for cardiovascular health, but the mechanism has not yet been discovered," said Dr Kaya. "We investigated the effects of passive smoking on the levels of three parameters - mean platelet volume (MPV), carboxyhemoglobin (COHb) and lactate - in an effort to further understand this mechanism. We also looked at the correlation between the three parameters."

27 Aug 2012

Mexican-Americans with ancestral links have higher insulin resistance levels

Mexican-Americans with an ancestral link to Amerindian tribes were found to have higher insulin resistance levels, which is an indication of several chronic conditions such as type 2 diabetes, according to research by The University of Texas Health Science Center at Houston (UTHealth).

26 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Genetic key to severe malaria resistance uncovered

Researchers have identified two genetic variants linked with human resistance to severe malaria.

21 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012